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  ABSTRACT 
  Objectives      Patients with advanced ankylosing 
spondylitis (AS) experience disability because of reduced 
spinal mobility and pulmonary function impairment. 
This placebo-controlled study evaluated the effect of 
etanercept (ETN) in patients with advanced AS.   
  Methods      A multicentre randomised double-blind 
placebo-controlled trial of 12 weeks’ duration was 
performed. Patients had deﬁ  nite (modiﬁ  ed New York 
criteria), active (Bath AS Disease Activity Index (BASDAI) 
≥40), severe (radiological intervertebral bridges) AS 
refractory to non-steroidal anti-inﬂ  ammatory drugs and 
were antitumour necrosis factor naive. They were treated 
with ETN 50 mg once weekly or identical placebo (PBO).   
  Results      Of the 95 patients screened, 82 were 
randomised to receive ETN (n=39) or PBO (n=43). 
At baseline the disease was active (mean BASDAI 
61.0±13.4, C reactive protein (CRP) 20.7±25.5 mg/l) 
and severe (mean Bath AS Metrology Index (BASMI) 
5.7±1.3, mSASSS 36.5±20.5); forced pulmonary 
vital capacity (FVC) was 3.3±0.7 l. Improvement in 
BASDAI (normalised net incremental area under the 
curve between baseline and week 12, primary end 
point) was signiﬁ  cantly greater in the ETN group than 
in the PBO group (−19.8±16.5 vs −11.0±16.4, 
p=0.019). Moreover, at week 12, ETN gave better 
results than PBO for the BASDAI (−26.4±19.7 vs 
−14.4±19.7; p=0.008), total back pain (−29.2±24.0 
vs −14.9±24.0; p=0.010), BASFI (−21.7±17.6 
vs −10.1±17.6; p=0.004), BASMI (−0.6±0.6 vs 
−0.2±0.6; p=0.011), CRP level (−15.7±14.2 vs 
−1.3±14.2; p<0.001) and FVC (+160±280 ml vs 
−20±280 ml; p=0.006).   
  Conclusions      ETN has short-term efﬁ  cacy for patients 
with advanced AS, as was previously reported for less 
advanced disease. The efﬁ  cacy is observed for the main 
symptoms (pain) and on markers of inﬂ  ammation (CRP), 
as well as disease severity in terms of spinal mobility and 
pulmonary  function.      
  INTRODUCTION 
  The principal concern of patients with ankylosing 
spondylitis (AS) is progression towards ankylosis 
and abnormal ﬁ  xed attitudes (eg, thoracic kypho-
sis). At the thoracic level, ankylosis is the conse-
quence of ossiﬁ   cation of the ligaments and the 
vertebrocostal and sternocostal joints.    1    Patients 
with advanced spinal ankylosis (ie, bamboo spine) 
experience signiﬁ   cantly more functional impair-
ment than do other patients with AS.    2    In patients 
with restricted chest wall motion, airﬂ  ow  mea-
surements are normal but vital capacity (VC) 
is decreased and functional residual capacity is 
increased.    3     –      5    
  Tumour necrosis factor (TNF) blockers have 
greatly improved the condition of patients with 
active inﬂ   ammatory spinal disease.    6     –      9    Most of 
these studies excluded patients with total spinal 
ankylosis.    6        7    
  In advanced structural disease (ie, patients with 
radiological evidence of vertebral fusion at sev-
eral levels of the spine), the question remains as 
to whether the symptoms are related to persistent 
inﬂ   ammation—which might be reversible after 
therapy with TNF blockers, for example—or only 
to the structural ossiﬁ  cation process which might 
be refractory to anti-inﬂ   ammatory therapy. The 
issues relate to symptoms (eg, pain, functional dis-
ability) and signs (eg, spinal mobility or pulmonary 
function). 
  To our knowledge, only three studies have 
reported the effect of TNF blockers in patients 
with advanced spinal disease, two of which were 
observational studies without a control group.    10        11    
The results of these two observational studies sug-
gested improvement of signs and symptoms with 
treatment in patients with advanced but still active 
spinal disease, similar to those in whom AS was 
not advanced. In fact, the single placebo-controlled 
study of this condition was also a post hoc analy-
sis of adalimumab in a phase III study (eg, ATLAS) 
evaluating 11 patients with total spinal ankylosis 
based on assessment of lateral radiographic views 
of the cervical and lumbar spine.    12    Clinical response 
(ie, ASAS20) at week 12 was achieved in three of 
six patients receiving adalimumab and none of ﬁ  ve 
patients receiving placebo. 
  Because these studies were weak in methodol-
ogy (not controlled or performed on small sample 
size) and because the question was relevant, we 
initiated a placebo-controlled trial to evaluate the 
effects of etanercept (ETN) on advanced AS in terms 
of symptoms (eg, pain and function) and signs (eg, 
spinal mobility and pulmonary function).   
  METHODS 
  Study  design 
  This was a 12-week randomised double-blind 
placebo-controlled multicentre study (clinical trial 
registration number NCT00420238) conducted in 
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stable. In case of a painful episode during the study, analgesics 
such as paracetamol, with or without codeine or dextropropoxy-
phen, could be used.   
  Outcome  measures 
  Patients were evaluated at screening, baseline and weeks 2, 4, 
8 and 12. 
  At each visit, disease was assessed by the Patient Global 
Assessment (PGA) (0–100 VAS), the BASDAI,    17    the Bath 
Ankylosing Spondylitis Functional Index (BASFI),    18    the Bath 
AS Metrology Index (BASMI)    19        20    and C reactive protein (CRP) 
level. Two further end points evaluated by the patients were 
the Minimum Clinically Important Improvement (MCII)    21    and 
Patient Acceptable Symptom State (PASS)    22    from weeks 2 to 12. 
The MCII consists of two questions aimed at deﬁ  ning whether 
the observed difference (eg, less pain) from baseline constitutes 
a trivial or an important improvement to patients, and the PASS 
consists of one question aimed at deﬁ  ning whether the observed 
changes lead to an acceptable symptom state according to the 
patient. 
  At weeks 0 and 12, pulmonary function tests (eg, VC, forced 
vital capacity (FVC), forced expiratory volume in 1 s (FEV  1  ) and 
the ratio (FEV  1  /FVC)) were locally performed in accordance 
with American Thoracic Society standards. Predicted values 
were obtained from European recommendations.    23      
  Sample  size  calculation 
  The planned sample size of 40 patients per group was suf-
ﬁ  cient to show a difference of 15 points for the primary end 
point (expected difference between groups in the normalised net 
incremental area under the curve for BASDAI) assuming a SD of 
20. This sample size was based on a power of 90% and a two-
sided type 1 error of 5%.   
  Statistical  analysis 
  The primary end point (eg, normalised net incremental area 
under the curve (AUC) in the BASDAI between randomisation 
(baseline) and week 12) was calculated as the area between 
baseline and the PGA curve as a function of time, using the 
linear trapezoidal method, divided by the number of days the 
patient remained in the study. It was analysed by an analysis 
of variance (ANCOVA) method with treatment as a factor and 
BASDAI baseline as a covariate. 
  A mixed model ANCOVA with an autoregressive correlation 
structure with treatment groups, visits and their interaction as 
ﬁ  xed factors and baseline scores as a covariate was also used 
to analyse changes from baseline in the BASDAI and other 
continuous secondary efﬁ  cacy variables such as the ASDAS.    24    
For binary efﬁ   cacy variables (ASAS20, ASAS40, ASAS5/6, 
ASAS partial remission, and improvement in BASDAI of at 
least 50% (BASDAI50), improvement in AS-DAS and AS-DAS 
status)    25     –       27    a generalised estimating equation model with a 
logit link, a binominal distribution and an autoregressive cor-
relation structure was used, with treatment groups, visits and 
their interaction as ﬁ  xed factors. The primary analysis was 
modiﬁ  ed intent-to-treat, which included all randomised sub-
jects who received at least one blinded dose of test article, 
with the last observation carried forward used for missing 
values. 
  The time to achieve a sustained acceptable symptom state by 
the PASS was estimated by the Kaplan–Meier method. The two 
survival curves were compared by the log-rank test.     
21 centres in four European countries (France, Germany, The 
Netherlands and Hungary) comparing ETN 50 mg subcutane-
ous injection once weekly, with placebo (PBO; 1:1 ratio). After 
a screening period of up to 6 weeks to ensure their eligibility 
to enter the study, patients were randomised to receive ETN 
or PBO. Patients were evaluated at screening, baseline and at 
weeks 2, 4, 8 and 12.   
  Patients 
  Men and women aged 18–70 years were eligible if they had a 
current diagnosis of AS as deﬁ  ned by the modiﬁ  ed New York 
criteria.    13    Patients with AS presented with one of the follow-
ing three criteria deﬁ  ning advanced and severe spinal ankylo-
sis: (1) two intervertebral adjacent bridges and/or fusion at the 
lumbar spine; (2) three intervertebral adjacent bridges and/or 
fusion at the thoracic spine; or (3) two intervertebral adjacent 
bridges and/or fusion at the cervical spine. Each investigator 
evaluated the disease at the screening visit from lateral radio-
graphic views of the cervical, thoracic and lumbar spine. Each 
investigator also evaluated the modiﬁ   ed Stoke Ankylosing 
Spondylitis Spine Score (mSASSS) on radiography.    14    Finally, 
from information provided by the investigator, the radio-
logical stage of disease    15    was determined on a scale of 0–V, 
stages I–III being moderate radiographic evidence of struc-
tural damage involving <50% of the spine (ie, ≤12 vertebrae) 
in two spinal segments, and stages IV and V being advanced 
AS with stage IV characterised by involvement of 50–80% of 
the spine in more than two spinal segments (ie, 13–19 ver-
tebrae) and stage V by involvement of ≥80% of the spine. 
Moreover, each investigator checked the radiological evidence 
of hip involvement from a pelvic x-ray evaluating the BASRI-
hip scoring system of 0–4 where 0 is normal, 1 is suspicious 
(possible focal joint space narrowing), 2 is minimal (deﬁ  nite 
narrowing, leaving a circumferential joint space >2 mm), 3 
is moderate (narrowing but with circumferential joint space 
≤2 mm or bone-on-bone apposition <2 cm) and 4 is severe 
(bone deformity or bone-on-bone apposition >2 cm or total 
hip replacement). In this report, radiological hip abnormali-
ties (coxitis) are considered as present if observed at either the 
right or left hip level with a BASRI-hip score of at least 2.    16    
Patients also had to have baseline pain with axial involvement 
of the overall level of AS neck, back or hip for a score ≥30 on a 
0–100 mm visual analogue scale (VAS). Finally, patients had to 
have an active refractory disease deﬁ  ned by a score ≥40 on the 
Bath AS Disease Activity Index (BASDAI) (0–100)    17    despite 
optimal non-steroidal anti-inﬂ  ammatory drug (NSAID) treat-
ment (at least two NSAIDs at the maximal tolerated dose for 
>3 months and according to the opinion of the investigator). 
Patients were excluded from the study if they had been pre-
viously exposed to a TNF inhibitor, if the NSAID dose had 
changed within 2 weeks of baseline evaluation and if the 
dose of concomitant conventional disease-modifying anti-
rheumatic drug (DMARD; eg, sulfasalazine, methotrexate), 
if taken, had changed within 4 weeks of baseline evaluation. 
Patients were also excluded if they had signiﬁ  cant concur-
rent medical disorders (eg, cancer or history of cancer, serious 
infection) and/or abnormal laboratory test results.   
  Interventions 
  Eligible patients giving informed consent were randomly 
assigned to receive either ETN 50 mg once weekly or match-
ing placebo. During the 12 weeks of the study the dose of con-
comitant NSAIDs and any concomitant DMARD had to remain 
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  Moreover, at week 12, according to the MCII, signiﬁ  cantly 
more patients in the ETN group were improved than in the 
PBO group, with 24 (63%) versus 14 (38%) patients showing 
very or moderately improved scores (p=0.025); according to 
the PASS, 23 (61%) versus 15 (41%) ETN- and placebo-treated 
patients, respectively, considered their condition as acceptable 
(p=0.065). 
  The onset of action of the treatment was quick, as the changes 
in BASDAI over time showed a signiﬁ  cant difference between 
groups in favour of etanercept from week 8 (−26.1±19.8 vs 
−13.6±19.7; p=0.005) and sustained until week 12 (−26.4±19.8 
vs −14.4±19.7; p=0.008) (  ﬁ  gure 2  ). Nine of 43 patients in the 
PBO group and 22 of 39 patients in the ETN group reported a 
sustained PASS over the 12 weeks. The median time to reach 
this status was 8 weeks (95% CI 3.9, NA) for the ETN group 
but could not be evaluated in the PBO group because fewer than 
50% of the patients experienced a sustained response (p=0.0009, 
log-rank test).   
  The ETN group therefore achieved quick onset of action 
(as early as week 2), with a statistically signiﬁ  cant difference 
between the two groups from week 8. 
  There was a trend in favor of ETN for all the clinically evalu-
ated parameters. Concerning spinal mobility measures, the 
responsiveness of the different components of the BASMI and 
also the chest expansion are shown in table S1 in the online 
supplement. These results suggest that the most responsive 
component is the spinal lateral ﬂ  exion, but only the changes 
in the composite index reached the intergroup statistical 
signiﬁ  cance. 
  RESULTS 
    Patients and study course 
  Of the 95 screened patients, 82 were eligible for randomisation 
in the study. The mean reasons for exclusion were low level of 
active disease (eg, BASDAI <40) or withdrawal of consent. Of 
the 82 enrolled patients, 39 received treatment with ETN and 43 
PBO. The two groups did not differ signiﬁ  cantly in demographic 
characteristics, symptomatic activity or severity of disease at 
baseline (  table 1  ). 
    Figure 1   illustrates the ﬂ   ow of patients during the study. 
Five patients dropped out of the study after randomisation: 
one patient in the ETN group after the ﬁ  rst injection following 
a detailed evaluation of a chest x-ray performed at screening 
which revealed a pre-existing lung neoplasm, four patients in 
the PBO group because of lack of efﬁ  cacy for two, withdrawal 
of consent for one and lost to follow-up for one.     
  Efﬁ  cacy 
  The mean±SD normalised net incremental AUC for the BASDAI 
(primary efﬁ  cacy end point) during the 12 weeks of treatment 
was signiﬁ  cantly greater for the ETN group than for the PBO 
group (−11±16 vs −20±17; p=0.019). 
  The ETN group showed signiﬁ  cantly better results than the 
PBO group for the responder criteria ASAS20 and ASAS5/6 
and for BASDAI50 but not ASAS40 and ASAS partial remission 
(  table 2  ).   
  Absolute changes between baseline and week 12 showed a 
statistically signiﬁ  cant difference favouring ETN (  table 3  ).   
  Table  1         Patient demographics and disease characteristics at baseline by treatment group   
 Characteristics 
 Treatment  group 
 All  (n=82)   Placebo  (n=43)   Etanercept  (n=39) 
Age, years 48±10 46±11 47±10
Men, n (%) 39 (91%) 37 (95%) 76 (93%)
Disease duration, years 23±11 19±10 21±11
HLA B27 positive, n (%) 36 (86%) 31 (79%) 67 (83%)
Past history or present symptoms, n (%)
  Peripheral arthritis 19 (44%) 18 (46%) 37 (45%)
  Enthesiopathy 18 (42%) 11 (28%) 29 (35%)
  Uveitis 12 (28%) 13 (33%) 25 (30%)
  Psoriasis 5 (12%) 4 (10%) 9 (11%)
Spinal radiological stage, n (%)
  II 3 (7%) 7 (18%) 10 (12%)
  III 26 (60%) 21 (54%) 47 (57%)
  IV 9 (21%) 7 (18%) 16 (20%)
  V 5 (12%) 4 (10%) 9 (11%)
Intervertebral radiological fusion (0–24) 10±6 9±6 10±6
Radiological mSASSS (0–72) 39±19 34±22 37±21
Radiological hip abnormalities (coxitis)* 14(35%) 12 (32%) 26 (33%)
BASDAI (0–100) 58±15 64±12 61±13
BASFI (0–100) 57±19 63±20 60±19
BASMI (0–10) 5.8±1.3 5.7±1.4 57±1.3
Total back pain (0–100) 61±20 70±16 65 (±19
CRP level, mg/l 17±19 25±31 21±26
ASDAS-CRP 3.63±0.76 3.90±0.71 3.76±0.75
Disease activity state, n (%)
  ASDAS-CRP <1.3 (inactive disease) 0 (0) 0 (0) 0 (0)
  ASDAS-CRP >1.3–<2.1 (moderate disease activity) 1 (2.4) 0 (0) 1 (1.3)
  ASDAS-CRP >2.1–<3.5 (high disease activity) 17 (41.5) 12 (30.8) 29 (36.3)
 ASDAS-CRP  ≥3.5 (very high disease activity) 23 (56.1) 27 (69.2) 50 (62.5)
   Data  are  mean±SD. 
  *On pelvic x-ray assessment (eg, BASRI-hip score of at least 2 at either the right or left hip). 
  ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, 
Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; mSASSS, 
modiﬁ  ed Stoke Ankylosing Spondylitis Spine Score.     
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  Safety 
  Overall, no unexpected adverse events or changes in laboratory 
values or vital signs were observed that gave cause for concern. 
A total of 28 patients in the PBO group (65%) and 24 patients in 
the ETN group (62%) experienced at least one adverse event. 
  Three patients were considered by the investigator to have a 
serious adverse event: one patient in the ETN group was diag-
nosed with a lung neoplasm after detailed evaluation of the 
chest x-rays performed at screening (this patient withdrew from 
the study at the time of the diagnosis, ie, after the ﬁ  rst injec-
tion), one patient in the ETN group experienced a ﬂ  uctuating 
mild to moderate asymptomatic neutropenia during the entire 
study, and one patient in the PBO group experienced aggravated 
AS which resulted in his withdrawal from the study at week 8. 
Adverse events occurred in at least 5% of patients; injection site 
reaction was the most frequent with three patients (8%) in the 
ETN group and none in the PBO group.     
  DISCUSSION 
  This study of AS patients with advanced spinal damage seen 
on x-rays demonstrates the short-term symptomatic efﬁ  cacy 
of ETN over PBO but also suggests that, despite such spinal 
ankylosis, ETN might improve spinal mobility and respiratory 
function. 
  The strengths of the study are its well-deﬁ  ned inclusion cri-
teria, a PBO-controlled group and an a priori chosen primary 
end point to evaluate the short-term efﬁ  cacy of ETN in symp-
toms of advanced AS. One of the difﬁ  culties in designing the 
trial was to deﬁ  ne clearly the radiological criteria for ‘advanced 
disease’. On the basis of the personal experience of the scientiﬁ  c 
committee in charge of the design of the protocol, the presence 
of intervertebral adjacent bridges (at least two at the lumbar or 
cervical spine level or three at the thoracic level) was considered 
advanced disease. A post hoc analysis of data collected by the 
local investigator allowed for categorising disease according to 
the radiological grade scale from I to IV.    15    Moreover, the mean 
mSASSS score we observed at baseline in the modiﬁ  ed intent-
to-treat population (36.5±20.5) was higher than the score from 
‘conventional’ studies evaluating the structural effect of TNF 
blockers (16±18, 18±18, 20±19 in the ETN,    28    inﬂ  iximab    29    and 
adalimumab    30    trials, respectively). In addition, the percentage of 
patients with a coxitis (eg, radiological hip abnormalities) was 
greater in the study population (eg, 33%), also reﬂ  ecting severe 
disease. The observed BASMI for spinal mobility at baseline was 
higher than that reported in previous studies (5.7±1.4 vs 3.7±2.2 
and 3.4±2.2 for etanercept and sulfasalazine baseline values in 
the ASCEND trial and 4.2±2.1 and 3.8±2.2 for adalimumab and 
placebo baseline values in the ATLAS trial).    8        31    These ﬁ  ndings 
conﬁ   rm the ‘advanced’ disease characteristic of our enrolled 
  There was also a trend in favor of ETN for all the evaluated 
pulmonary tests and, in particular, at the end of the 12-week 
study, there was a lower percentage of patients with a pulmo-
nary restrictive pattern. The results related to pulmonary func-
tion tests are shown in   table 4  .     
  Figure  1      Flow  of  patients  through  the  trial.    
  Table  2         Responder criteria after 12 weeks of therapy by treatment group   
 Responder  criteria 
 Treatment  group 





ASAS20 14 (33%) 25 (67%) 0.003
ASAS40 10 (23%) 17 (44%) 0.053
ASAS5/6  2  (5%)  8  (21%) 0.044
ASAS partial remission   2 (5%)   7 (18%) 0.073
BASDAI 50 10 (23%) 18 (46%) 0.031
ASDAS-CRP changes (W12-baseline)
   ASDAS  ≥1.1 (minimally important 
improvement)
  7 (17.1) 25 (64.1) <0.0001
   ASDAS  ≥2.0 (major improvement)   1 (2.4) 15 (38.5) <0.0001
ASDAS-CRP status at W12
  ASDAS <1.3 35 (85.4) 17 (43.6) <0.001
 ASDAS  <2.1 41 (100) 25 (64.1) <0.0001
      ASAS, Ankylosing Spondylitis Activity Score; ASDAS, Ankylosing Spondylitis Disease 
Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.     
  Table  3         Absolute changes between baseline and week 12 in parameters by treatment group   
 Parameter 
  Baseline (week 0)   Week  12    Adjusted changes (week 12–week 0) 
 p  Value  Placebo* (n=43) Etanercept* (n=39) Placebo* (n=43) Etanercept* (n=39) Placebo† (n=43) Etanercept† (n=39)
BASDAI (0–100) 58±15 64±12 45±19 37±26 −14±20 −26±20 0.008
BASFI (0–100) 57±19 63±20 48±21 41±29 −10±18 −22±18 0.004
BASMI, (0–10) 5.8±1.3 5.7±1.4 5.6±1.3 5.1±1.7 −0.20±0.65 −0.57±0.65 0.011
Total back pain, (0–100) 61±20 70±16 48±22 38±28 −15±24 −29±24 0.010
CRP, mg/l 17±19 25±31 18±20 6±8 −1±14 −16±14 <0.0001
ASDAS-CRP 3.63±0.76 3.90±0.71 3.18±0.95 2.3±0.97 −0.49±0.87 −1.51±0.87 <0.0001
   *Data  are  mean±SD. 
  †Data are adjusted mean±SD from a mixed model ANCOVA with an autoregressive correlation structure with treatment groups, visits and their interaction as ﬁ  xed factors and baseline 
scores as a covariate. 
  ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; 
BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein.     
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pattern is a consequence of reduced mobility of the thoracic 
cage.    3    To our knowledge, this study is the ﬁ   rst to evaluate 
systematically the treatment effect of TNF blockers on these 
parameters.    35    The signiﬁ  cant improvement in FVC of 160 ml 
observed in the ETN group compared with a decrease of 20 ml 
in the PBO group after 12 weeks is encouraging and should be 
interpreted in the light of the short treatment period. 
  The relatively short time period of our study could be con-
sidered a limitation. However, the rapid onset of action and the 
sustainability of the response with ETN demonstrate its symp-
tomatic efﬁ  cacy. 
  Although the study was not designed to assess the potential 
toxicity of ETN, we observed no unexpected adverse events. 
  In summary, this is the ﬁ  rst prospective randomised place-
bo-controlled study speciﬁ   cally designed to evaluate ETN in 
advanced active AS disease; it demonstrates a symptomatic clin-
ically relevant and statistically signiﬁ  cant beneﬁ  t. The next step 
will be to determine the optimal management for this popula-
tion in the long term.       
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patients. Besides this structural severity, patients had active dis-
ease at baseline as determined by both the BASDAI (61±13) and 
CRP level (21±26 mg/l), which were similar to values from clini-
cal trials evaluating TNF blockers (61±15 and 20±21 mg/l in the 
ETN trial    6    and 63±17 and 21±27 mg/l in the adalimumab trial).    8    
  ETN gave statistically signiﬁ  cant higher values for most vari-
ables of efﬁ  cacy. In addition, these results conﬁ  rm the higher 
discriminant capacity of ASDAS-CRP compared with the con-
ventional BASDAI score.    32    Indeed, we observed the highest sta-
tistically signiﬁ  cant intergroup difference for the ASDAS-CRP 
parameter. The magnitude of the effect in terms of change in 
status (eg, ASAS20 responder criteria: 67% vs 33% in the ETN 
vs placebo group) was similar to that observed in clinical tri-
als evaluating TNF blockers in patients with active AS but less 
advanced disease. The main difference is from results evaluat-
ing the status at the end of the trial in terms of spinal mobility 
or functional impairment—for example, in our study the BASFI 
score decreased from 63 to 41 after ETN therapy (ie, a clinically 
relevant change but still residual relevant functional disabil-
ity), whereas in the previous trials of ETN in patients with less 
advanced disease the BASFI score decreased from 61 to 32 after 
12 weeks of therapy.    33    Such ﬁ  ndings suggest that TNF blockers 
are still of use for patients with active advanced disease but, 
also for this condition, a ‘ﬂ  oor’ effect can be observed because 
of the underlying structural damage. This ﬁ  nding suggests ini-
tiation of treatment at an early stage of the disease.    34    
  The results observed in pulmonary function are also interest-
ing. Most of the patients exhibited a typical restrictive pattern 
at baseline (FVC ≥80%, commonly used to assess restrictive 
pulmonary defect). One previous study has shown that this 
  Figure  2         Absolute changes in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) from baseline during the 12 weeks of the study by 
treatment group (etanercept vs placebo).       
  Table  4         Changes in pulmonary function during the 12 weeks of the study by treatment group   
 Parameter 
  Baseline (week 0)   Week  12 
 Adjusted  changes 
(week 12–week 0) 
 p  Value   Placebo*   Etanercept*   Placebo*   Etanercept*   Placebo†   Etanercept† 
VC (l) 3.39±0.74 3.48±0.79 3.35±0.76 3.58±0.81 −0.05±0.26 +0.14±0.26 0.003
FVC (l) 3.25±0.73 3.33±0.74 3.23±0.79 3.47±0.78 −0.02±0.28 +0.16±0.28 0.006
FEV  1   (l) 2.65±0.65 2.80±0.70 2.62±0.66 2.83±0.71 −0.02±0.22 +0.05±0.22 0.205
Ratio FEV  1 /FVC  (%) 81.86±10.09 83.87±8.75 81.52±10.87 81.40±8.73 +0.10±5.05 −2.5±5.05 0.030
VC (% of predicted) 80.02±19.68 79.26±16.76 79.12±17.90 81.55±16.53 −1.44±5.76 +2.88±5.76 0.002
FVC (% of predicted) 78.98±14.88 78.51±15.59 78.96±17.28 81.71±15.80 −0.33±6.59 +3.75±6.59 0.009
Patients with restrictive pattern (FVC ≤80%), n(%) 24 (57.1%)‡ 21 (55.3%)‡ 27 (71.1%)‡ 16 (43.2%)‡ – – 0.032§
   *Data  are  mean±SD. 
  †Data are adjusted mean±SD from a mixed model ANCOVA with an autoregressive correlation structure with treatment groups, visits and their interaction as ﬁ  xed factors and baseline 
scores as a covariate. 
  ‡Data are number (%) of patients. 
  §Statistically signiﬁ  cant (Fisher exact test). 
 FEV 1  , forced expiratory volume in 1 second; FVC, forced vital capacity; VC, vital capacity.     
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